About
A Self-Sustaining Path to New Medicines.
We develop biologics for dogs and cats, funded by a foundation business that turns a profit every year.
- Founded 2021
- Daejeon
- 15 Employees
- Certified Venture Company
- Registered Corporate Research Institute
Vision & Mission
Human-Grade Biologics, Made for Companion Animals
SmartGene redesigns targets validated in humans for the species that need them, developing biologics made specifically for companion animals. We are building the next stage of companion-animal medicine on the foundation of making research reagents and laboratory software.
Four Pillars
Platform
CHO-Speed™ stable cell line technology, driven by the SGTNase™ transposon, underpins every programme.
R&D
Awarded a national bispecific-antibody R&D grant; registered corporate research institute; certified venture company.
Execution
GMP manufacture and clinical work run with established CDMOs and CROs. Capital expenditure stays minimal and the team stays focused.
Foundation Business
Research reagents, kits and laboratory software support operations and fund pipeline development.
From the CEO
From Making Reagents to Making Medicines for Companion Animals
SmartGene began in 2021 with a promise: get researchers the right reagent, on time. We kept it, and we have been profitable every year since — and that profit is what makes our next step possible.
Companion animals have long depended on medicines built for people or for other species. We believe that gap closes when a target already validated in humans is redesigned for dogs and cats. Our own CHO-Speed™ cell line platform is turning that belief into five programmes.
We are a small company, and that is exactly why we work honestly. We promise what we can make, and we make what we promise. Our thanks go to our partners, our investors, and the researchers who have stayed with us.
Not the biggest, but giving our best — that is the SmartGene we intend to be.
Hee-Myeong Kim, CEO, SmartGene Inc.
Core Values
How SmartGene Works
We're small, but we've held onto a few principles for growing alongside the research community.
Quality First
From raw material selection to the finished product, we manage every step in-house so researchers can trust the reagents and kits they're working with.
Customer-Centered
We listen closely to even the small frustrations of lab work, and start every product and service decision from what actually helps in practice.
Steady Growth
Rather than settling into our current business, we're taking deliberate steps into new territory — CRO services and animal biologics & new drug development.
Trust & Expertise
Built on years of manufacturing and distribution know-how, we're earning long-term trust with universities, corporations, and public research institutes.
History
From Reagent Company to Biotech
2021
SmartGene Inc. founded in Daejeon
Since founding
Certified as a venture company; a nationwide network of 50 distributors built
Platform
CHO-Speed™ platform and SGTNase™ developed; two core platform patents
2026
Transition to companion-animal biopharmaceutical developer — corporate research institute registered, national bispecific-antibody R&D grant awarded, KBSI structural analysis project selected, STAR-K9E candidate nominated
Company Info
Company Information
- Company
- SmartGene Inc.
- CEO
- 김희명 / Hee-Myeong Kim
- Biz Reg. No.
- 722-88-02047
- Founded
- 2021
- Employees
- 15
- Certifications
- Certified venture company · Registered corporate research institute
- Address
- 602, D-dong, Daedeok Biz Center, 17, Techno 4-ro, Yuseong-gu, Daejeon, Korea 34013
- Phone
- +82-42-226-9336
- Fax
- +82-42-226-9338
- info@smartgene.co.kr